The compound was developed in partnership between University of New Mexico (UMN) and the University of Florida and Oligocide licensed it in June and received $175,000 in seed funding from angel investors the following month.
Oligocide, a US-based company whose chemical kills bacteria, is preapring to potential raise its series A round with corporate venturing units. The compound was developed in partnership between University of New Mexico (UMN) and the University of Florida and Oligocide licensed it in June and received $175,000 in seed funding from angel investors the following…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
